SEP 10, 2026 · PHASE 2/3 TRIAL
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
ClinicalTrials.gov
This is an active registry record for a Phase 2/3 interventional trial with no posted results; it describes planned enrollment and methodology only.
Reported
Estimated enrollment80
Primary outcome measureComplete response rates within 28 weeks of…
Follow-up duration28 weeks